[{"id":"3a50b208-77fa-4a62-b800-7df7cd0b150e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02854839","created_at":"2021-01-18T14:01:14.066Z","updated_at":"2024-07-02T16:36:55.164Z","phase":"Phase 2a","brief_title":"A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma","source_id_and_acronym":"NCT02854839","lead_sponsor":"GC Cell Corporation","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MG4101"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 09/27/2018","primary_completion_date":" 09/27/2018","study_txt":" Completion: 09/17/2019","study_completion_date":" 09/17/2019","last_update_posted":"2019-09-26"}]